CY2012014I2 - Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης - Google Patents

Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης

Info

Publication number: CY2012014I2
Authority: CY; Cyprus
Prior art keywords: tegafur; administration; toxicity due; gastrointestinal toxicity; reducing gastrointestinal
Prior art date: 2004-04-29

Application number

CY2012014C

Other languages

English (en)

Other versions

CY2012014I1 (el

Original Assignee

Taiho Pharmaceutical Company, Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-29

Filing date

2012-05-31

Publication date

2016-04-13

2012-05-31 Application filed by Taiho Pharmaceutical Company, Limited filed Critical Taiho Pharmaceutical Company, Limited

2016-04-13 Publication of CY2012014I1 publication Critical patent/CY2012014I1/el

2016-04-13 Publication of CY2012014I2 publication Critical patent/CY2012014I2/el

Links

206010059024 Gastrointestinal toxicity Diseases 0.000 title 1
231100000414 gastrointestinal toxicity Toxicity 0.000 title 1
WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 title 1
229960001674 tegafur Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CY2012014C 2004-04-29 2012-05-31 Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης CY2012014I2 (el)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US56618004P	2004-04-29	2004-04-29
PCT/JP2005/008450 WO2005105086A1 (en)	2004-04-29	2005-04-27	Method for reducing gastrointestinal toxicity due to the administration of tegafur

Publications (2)

Publication Number	Publication Date
CY2012014I1 CY2012014I1 (el)	2016-04-13
CY2012014I2 true CY2012014I2 (el)	2016-04-13

Family

ID=35241420

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CY20121100222T CY1112451T1 (el)	2004-04-29	2012-03-07	Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης
CY2012014C CY2012014I2 (el)	2004-04-29	2012-05-31	Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CY20121100222T CY1112451T1 (el)	2004-04-29	2012-03-07	Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης

Country Status (16)

Country	Link
US (1)	US20080166427A1 (el)
EP (1)	EP1750703B1 (el)
JP (1)	JP5376758B2 (el)
AT (1)	ATE540679T1 (el)
AU (1)	AU2005237364B2 (el)
CY (2)	CY1112451T1 (el)
DK (1)	DK1750703T3 (el)
ES (1)	ES2378072T3 (el)
HR (1)	HRP20120293T1 (el)
ME (1)	ME01335B (el)
PL (1)	PL1750703T3 (el)
PT (1)	PT1750703E (el)
RS (1)	RS52217B (el)
RU (1)	RU2348409C2 (el)
SI (1)	SI1750703T1 (el)
WO (1)	WO2005105086A1 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010131769A1 (en) *	2009-05-13	2010-11-18	Taiho Pharmaceutical Co., Ltd.	Treatment of diffuse-type gastric cancers using s-1 and cisplatin
CA2768488A1 (en) *	2009-07-17	2011-01-20	Myriad Genetics, Inc.	Method of assaying 5-fu
WO2011022174A1 (en) *	2009-08-21	2011-02-24	Myriad Genetics, Inc.	Method of processing blood samples containing 5-fu
EP2422815A1 (en)	2010-08-18	2012-02-29	Grindeks, a joint stock company	Pharmaceutical composition of tegafur and natural flavonoid derivative catechin for potentiating antitumour effect and for treating tumours
EP2422848A1 (en)	2010-08-18	2012-02-29	Grindeks, a joint stock company	Composition of tegafur, Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
EP2422784A1 (en)	2010-08-18	2012-02-29	Grindeks, a joint stock company	Composition of TEGAFUR, caffeic acid phenethyl ester (CAPE) and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
US10172839B2 (en)	2014-03-06	2019-01-08	University Of Southern California	Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
JP6859567B2 (ja) *	2014-03-06	2021-04-14	ユニヴァーシティオブサザンカリフォルニアＵｎｉｖｅｒｓｉｔｙｏｆＳｏｕｔｈｅｒｎＣａｌｉｆｏｒｎｉａ	従来の化学療法剤の効力および実行可能性を増強し、かつ正常な細胞および組織におけるキナーゼの副作用を逆転させるための、キナーゼ阻害剤と併用した短期間絶食レジメンの使用
US10117872B2 (en) *	2014-03-28	2018-11-06	Università Degli Studi Di Genova	Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
US20180110780A1 (en) *	2015-04-30	2018-04-26	Taiho Pharmaceutical Co., Ltd.	Agent for alleviating side effect of antitumor drug
JP6439761B2 (ja) *	2016-08-09	2018-12-19	トヨタ自動車株式会社	ＮＯｘ吸蔵還元触媒の製造方法
CN106619689B (zh) *	2016-12-30	2018-05-01	陈晓华	一种用于治疗癌症的药物组合物、试剂盒及其应用
KR20230012572A (ko) *	2020-05-19	2023-01-26	셀릭스 바이오 프라이빗 리미티드	암을 치료하기 위한 약학 제형 및 이의 제조

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3635946A (en) *	1969-07-22	1972-01-18	Solomon Aronovich Giller	N1-(2'-furanidyl)-derivatives of 5-substituted uracils
DK175432B1 (da) *	1984-10-30	2004-10-18	Otsuka Pharma Co Ltd	Middel til forögelse af anticancervirkningen af anticancerforbindelser
US5968914A (en) *	1987-10-28	1999-10-19	Pro-Neuron, Inc.	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
NL194430C (nl) *	1989-01-05	2002-04-04	Otsuka Pharma Co Ltd	Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking.
EP0543015B1 (en) *	1991-05-27	1998-11-11	Taiho Pharmaceutical Co., Ltd.	Composition, method and kit for potentiating antitumor activity and for curing tumor
US6538001B1 (en) *	1998-10-12	2003-03-25	Nikolai Borisovich Leonidov	Crystalline modification of 5-fluoro-1-(tetrahydro-2-furyl) uracil and complex compounds based thereon, producing antineoplastic effect

2005
- 2005-04-27 AT AT05738545T patent/ATE540679T1/de active
- 2005-04-27 HR HR20120293T patent/HRP20120293T1/hr unknown
- 2005-04-27 AU AU2005237364A patent/AU2005237364B2/en not_active Ceased
- 2005-04-27 DK DK05738545.2T patent/DK1750703T3/da active
- 2005-04-27 ES ES05738545T patent/ES2378072T3/es not_active Expired - Lifetime
- 2005-04-27 US US11/587,643 patent/US20080166427A1/en not_active Abandoned
- 2005-04-27 JP JP2006539166A patent/JP5376758B2/ja not_active Expired - Fee Related
- 2005-04-27 RU RU2006142101/14A patent/RU2348409C2/ru active
- 2005-04-27 EP EP05738545A patent/EP1750703B1/en not_active Expired - Lifetime
- 2005-04-27 PT PT05738545T patent/PT1750703E/pt unknown
- 2005-04-27 WO PCT/JP2005/008450 patent/WO2005105086A1/en not_active Ceased
- 2005-04-27 ME MEP-2012-42A patent/ME01335B/me unknown
- 2005-04-27 RS RS20120127A patent/RS52217B/sr unknown
- 2005-04-27 PL PL05738545T patent/PL1750703T3/pl unknown
- 2005-04-27 SI SI200531451T patent/SI1750703T1/sl unknown
2012
- 2012-03-07 CY CY20121100222T patent/CY1112451T1/el unknown
- 2012-05-31 CY CY2012014C patent/CY2012014I2/el unknown

Also Published As

Publication number	Publication date
SI1750703T1 (sl)	2012-02-29
US20080166427A1 (en)	2008-07-10
JP5376758B2 (ja)	2013-12-25
AU2005237364A1 (en)	2005-11-10
ME01335B (me)	2013-12-20
RU2006142101A (ru)	2008-06-20
AU2005237364B2 (en)	2010-07-08
EP1750703B1 (en)	2012-01-11
CY2012014I1 (el)	2016-04-13
PT1750703E (pt)	2012-02-23
EP1750703A4 (en)	2008-02-27
RS52217B (sr)	2012-10-31
ATE540679T1 (de)	2012-01-15
PL1750703T3 (pl)	2012-05-31
DK1750703T3 (da)	2012-05-07
JP2007534634A (ja)	2007-11-29
HRP20120293T1 (hr)	2012-04-30
RU2348409C2 (ru)	2009-03-10
EP1750703A1 (en)	2007-02-14
ES2378072T3 (es)	2012-04-04
WO2005105086A1 (en)	2005-11-10
CY1112451T1 (el)	2015-12-09

Publication	Publication Date	Title
CY2012014I2 (el)	2016-04-13	Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης
CY2022001I1 (el)	2022-03-24	Παραγωγα του uk-2a
NL300885I2 (nl)	2022-02-24	Irinotecansucrosofaatzout
IS8578A (is)	2006-12-08	3- karbamoýl - 2- pýridón afleiður
DK2253614T3 (da)	2013-01-07	IAP-inhibitorer
DK1778718T3 (da)	2014-11-10	Iap-inhibitorer
EP1741703A4 (en)	2009-11-25	pyridone
DK1919907T3 (da)	2011-04-18	Heterocyklisk forbindelse
DE602005025715D1 (de)	2011-02-17	Kondensator
ATE400271T1 (de)	2008-07-15	Aryl-pyridinderivate als 11-beta-hsd1-hemmer
BRPI0511900A (pt)	2008-01-22	composições farmacêuticas
ATE394399T1 (de)	2008-05-15	Tetrahydropyridoindolderivate
ATE540935T1 (de)	2012-01-15	Chinazolinderivate
ATE420076T1 (de)	2009-01-15	Indozolonderivate als 11b-hsd1-inhibitoren
ATE553079T1 (de)	2012-04-15	Heteroarylphenylharnstoffderivat
DK1761541T3 (da)	2008-04-28	Pyrrazolo-pyrimidin-derivater
EP1872294A4 (en)	2010-10-27	VIRTUAL EARTH
DK2783682T3 (da)	2019-08-12	Farmaceutisk sammensætning omfattende pimobendan
ATE417830T1 (de)	2009-01-15	Sulfonylbenzimidazolderivate
EP1765192A4 (en)	2012-10-31	RECOVERY DEVICE
ATE412651T1 (de)	2008-11-15	Pyrrolopyridinderivate
NO20070299L (no)	2007-03-26	Novel heterocyclic compounds
ITMI20042238A1 (it)	2005-02-19	Composti per fluoropolirterei
EP1776112A4 (en)	2009-11-25	HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL AGENTS
ATE430142T1 (de)	2009-05-15	Phenylpiperazin-methanon-derivate